Breakthrough Study Reveals Polyamines as Potential SQTS3 Heart Treatment

Scientists have uncovered a potential new treatment for Short QT Syndrome type 3 (SQTS3), a rare genetic disorder linked to dangerous heart rhythm disturbances. Their study shows that polyamines, naturally occurring compounds, can correct defective sodium channel activity in the heart. This discovery offers hope for patients with limited existing treatment options. SQTS3 is caused by mutations in the SCN5A gene, which disrupts the cardiac sodium channel’s late current. This accelerates the heart’s electrical recovery, shortening the QT interval on an electrocardiogram. The condition increases the risk of syncope, atrial fibrillation, ventricular tachycardia, and sudden cardiac death.

Researchers found that polyamines interact with specific sites on the sodium channel’s alpha subunit. This interaction prolongs the action potential duration, effectively normalising the QT interval. The study confirmed that polyamine treatment extends late inward sodium currents in heart cells carrying the mutant SCN5A channels.

Pharmacokinetic tests revealed that the polyamine compounds used in the study are well-absorbed and effectively reach cardiac tissue. Computational models further explained how electrostatic and steric properties enable polyamines to bind to the channel and modulate its function. The findings highlight polyamines as promising candidates for SQTS3 therapy. Their ability to target the underlying channel dysfunction addresses a critical unmet need. Further long-term studies are required to refine dosing and assess sustained safety and efficacy.